Replies to post #190923 on Biotech Values

[DewDiligence]

…GILD likes to acquire earlier (I believe a few of the private companies were still P2 assets).

Agreed; John Milligan said on the 1Q15 CC that GILD likes to have a say in the design of phase-3 trials.